Literature DB >> 3465027

Colloidal bismuth subcitrate and ranitidine in the short-term treatment of benign gastric ulcer. An endoscopically controlled trial.

F Parente, M Lazzaroni, M Petrillo, G Bianchi Porro.   

Abstract

Colloidal bismuth subcitrate (CBS) in the form of a chewable tablet has been compared with ranitidine in the short-term treatment of benign gastric ulcers. Eighty patients were admitted to this randomised single blind study. Endoscopic control was carried out after 4 weeks, and after 8 weeks when healing was incomplete or had not occurred at the 4-week examination. After 1 month of therapy the healing rates were 70% with CBS and 62.5% with ranitidine (P = not significant). At two months the corresponding cure rates were 87.5% and 79%, respectively (P = not significant). Antacid consumption was higher in the group treated with ranitidine, but the difference was not statistically significant. Patient cooperation was good and similar in the two groups. These findings confirm that CBS, in tablet form, is at least as effective as ranitidine in the acute treatment of benign gastric ulcers.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3465027     DOI: 10.3109/00365528609102586

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  3 in total

1.  Short-term treatment of gastric ulcer. A meta-analytical evaluation of blind trials.

Authors:  F Di Mario; G Battaglia; G Leandro; G Grasso; F Vianello; S Vigneri
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

Review 2.  Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.

Authors:  A J Wagstaff; P Benfield; J P Monk
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

Review 3.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.